Kumar Neil reported option exercise involving 6,520 shares of BridgeBio Pharma, Inc. on Aug 16, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Executive Officer
Chief Executive Officer
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
6,520Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
314,544Direct
Trade date
Aug 16, 2026Option exercise
Filed
Aug 18, 2026, 6:02 PM ET2-day reporting delay
Accession
0001470831-26-000836Code M · Transaction 4256
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 16, 2026Option exercise33,544$0.00$0Trade 4258
Aug 16, 2026Option exercise19,599$0.00$0Trade 4259
Aug 16, 2026Option exercise11,554$0.00$0Trade 4260
Aug 16, 2026Option exercise6,520$0.00$0Trade 4261
Aug 16, 2026Tax withholding36,237$79.86−$2,893,886.82Trade 4257
Aug 16, 2026Option exercise33,544——Trade 4253
Aug 16, 2026Option exercise19,599——Trade 4254
Aug 16, 2026Option exercise11,554——Trade 4255
9 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

BBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.9%1w ago +1.8%1d ago −3.8%
Returns since7d −2.7%30d −19%90d180d1y

Footnotes in full

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. F4: Reflects a prior transfer of 750,000 shares of Common Stock from the Kumar Haldea Revocable Trust to the NK 2026 GRAT. The transfer constituted only a change in form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. F6: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.